Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

Neurology

Volumn 82, Issue 17, 2014, Pages 1499-1507

  Christensen, Jeppe Romme ^a   Ratzer, Rikke ^a   Börnsen, Lars ^a   Lyksborg, Mark ^a   Garde, Ellen ^a   Dyrby, Tim B ^a   Siebner, Hartwig R ^a   Sorensen, Per S ^a   Sellebjerg, Finn ^a  

^a Danish Multiple Sclerosis Center Department of Neurology Copenhagen University Hospital ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; NATALIZUMAB; NEUROFILAMENT PROTEIN; OSTEOPONTIN;

ADULT; ARTICLE; AXONAL INJURY; CLINICAL ARTICLE; DEMYELINATION; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SHORT FORM 36; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WHITE MATTER;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CEREBRAL CORTEX; CHEMOKINE CXCL13; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEINS; OSTEOPONTIN; RECURRENCE; TREATMENT OUTCOME;

EID: 84902186393     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000361     Document Type: Article

References (40)

1. Confavreux C, Vukusic S, Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430-1438.
2. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647-656.
3. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128:2705-2712. (Pubitemid 41552953)
4. Frischer JM, Bramow S, Dal-Bianco A, et al The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132:1175-1189.
5. Howell OW, Reeves CA, Nicholas R, et al Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134:2755-2771.
6. Bielekova B, Becker BL Monoclonal antibodies in MS: mechag nisms of action. Neurology 2010; 74(SUPPL. 1): S31-S40.
7. Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008; 18:563-576.
8. Romme Christensen J., Bornsen L, Khademi M., et al CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2013; 19: 877-884.
9. Polman CH, Reingold SC, Edan G, et al Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58:840-846. (Pubitemid 41746873)
10. Ravnborg M, Gronbech-Jensen M, Jonsson A. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult Scler 1997; 3:31-42. (Pubitemid 27234860)
11. Ware JE J.r., Sherbourne CD The MOS 36-Item Short-Form Health Survey (SF-36): I: conceptual framework and item selection. Med Care 1992; 30:473-483.
12. Cohen JA, Reingold SC, Polman C.H., Wolinsky JS Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012; 11:467-476.
13. Khademi M, Bornsen L, Rafatnia F., et al The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009; 16:528-536.
14. Miller DH, Soon D, Fernando K.T., et al MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68:1390-1401. (Pubitemid 46659091)
15. Vidal-Jordana A., Sastre-Garriga J, Perez-Miralles F, et al Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19: 1175-1181.
16. Zhang J, Waubant E, Cutter G., Wolinsky JS, Glanzman R EDSS variability before randomization may limit treatment discovery in primary progressive MS. Mult Scler 2013; 19:775-781.
17. Chabas D, Baranzini SE, Mitchell D, et al The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-1735. (Pubitemid 33104847)
18. Sinclair C, Mirakhur M, Kirk J., Farrell M, McQuaid S. Up-regulation of osteopontin and alphaB-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005; 31:292-303. (Pubitemid 40769528)
19. Hur EM, Youssef S, Haws M.E., Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8:74-83. (Pubitemid 46242361)
20. Bornsen L, Khademi M, Olsson T., Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011; 17:32-42.
21. Chowdhury SA, Lin J, Sadiq SA Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008; 65:232-235. (Pubitemid 351240786)
22. Khademi M, Kockum I, Andersson M.L., et al Cerebro-spinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011; 17:335-343.
23. Norgren N, Sundstrom P, Svenningsson A., Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63:1586-1590. (Pubitemid 39507573)
24. Orbach R, Zhao Z, Wang Y.C., O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One 2012; 7: e45409.
25. Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O., Miller DH, Thompson AJ Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008; 65:1454-1459.
26. Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001; 56:926-933. (Pubitemid 32290810)
27. Filippi M, Rocca MA, Barkhof F, et al Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012; 11:349-360.
28. Moll NM, Rietsch AM, Thomas S, et al Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 2011; 70:764-773.
29. Zivadinov R, Dwyer MG, Hussein S, et al Voxel-wise magnetization transfer imaging study of effects of natali-zumab and IFNbeta-1a in multiple sclerosis. Mult Scler 2012; 18:1125-1134.
30. Fox RJ, Cronin T, Lin J., et al Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 2011; 32:85-91.
31. De Stefano N., Giorgio A, Battaglini M., et al Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74:1868-1876.
32. Geurts JJ, Calabrese M, Fisher E., Rudick RA Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082-1092.
33. Tzartos JS, Friese MA, Craner M.J., et al Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172:146-155. (Pubitemid 351186376)
34. Romme Christensen J., Bornsen L, Ratzer R., et al Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One 2013; 8: e57820.
35. Gunnarsson M, Malmestrom C, Axelsson M., et al Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69:83-89.
36. Sato W, Tomita A, Ichikawa D., et al CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopon-tin in the pathogenesis of multiple sclerosis. J Immunol 2012; 189:5057-5065.
37. Serafini B, Rosicarelli B, Magliozzi R., Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164-174. (Pubitemid 38656388)
38. Lindberg RL, De Groot CJ, Montagne L, et al The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001; 124: 1743-1753. (Pubitemid 32845436)
39. Zhao C, Fancy SP, ffrench-Constant C, Franklin RJ Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination. Neurobiol Dis 2008; 31:209-217.
40. Gan HK, Grothey A, Pond G.R., Moore MJ, Siu LL, Sargent D. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 2010; 28:2641-2647.